Nasdaq:US$16.50 (+0.14) | HKEX:HK$26.00 (-0.10) | AIM:£2.70 (-0.01)
Search
EN
简
繁
About Us
Overview
Corporate Information
Board of Directors
Leadership
Sustainability
Contact Us
What We Do
Overview
Research and Development
Commercialization in China
Other Ventures
Key Corporate Partnerships
Pipeline & Products
Overview
Our Products
Our Pipeline
Expanded Access
News & Publications
News & Press Releases
Scientific Publications
Mailing List Sign-up
Shareholder Information
Overview
Announcements
Events, Presentations & Circulars
Share Price & Chart
Major Shareholders
Financial Reports & Filings
Analyst Coverage
Listing FAQs for Shareholders
Information for Shareholders
Corporate Governance
AIM Rule 26
Dissemination of Corporate Communications
Modern Slavery and Human Trafficking Statement
Careers
About Us
Overview
Corporate Information
Board of Directors
Leadership
Sustainability
Contact Us
What We Do
Overview
Research and Development
Commercialization in China
Other Ventures
Key Corporate Partnerships
Pipeline & Products
Overview
Our Products
Our Pipeline
Expanded Access
News & Publications
News & Press Releases
Scientific Publications
Mailing List Sign-up
Shareholder Information
Overview
Announcements
Events, Presentations & Circulars
Share Price & Chart
Major Shareholders
Financial Reports & Filings
Analyst Coverage
Listing FAQs for Shareholders
Information for Shareholders
Corporate Governance
AIM Rule 26
Dissemination of Corporate Communications
Modern Slavery and Human Trafficking Statement
Careers
Search Result
Chi-Med
Search Result
| 演示文稿
Previous Article
|
Next Article
演示文稿
,
科学出版物
| 29 Sep 2019
ESMO 2019: 索凡替尼用于治疗高分化的晚期非胰腺神经内分泌瘤患者的疗效和安全性
标题:
索凡替尼用于治疗高分化的晚期非胰腺神经内分泌瘤患者的疗效和安全性:
随机化的
III期临床试验(SANET-ep)结果
报告人:
中国人民解放军总医院第五医学中心 消化肿瘤科主任 徐建明
摘要编号:
LBA76
日期及时间:
2019年9月29日(星期日),巴塞罗那当地时间(CEST)16:30
报告地点:
Tarragona Auditorium (Hall 7), Fira de Barcelona Gran Via Conference Centre